A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

Phase 1

Completed

• Conditions: Metabolism and Nutrition Disorder; Obesity
• Interventions: Drug: placebo; Drug: NNC0165-1562

• Registration Number: NCT02568306
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This trial is conducted in the United States of America. The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses and multiple doses of NNC0165-1562 in overweight to obese but otherwise healthy subjects.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-10-02
• Study First Submitted QC: 2015-10-02
• Study Start: 2015-10-05
• Study First Posted: 2015-10-05
• Primary Completion: 2017-02-07
• Study Completion: 2017-02-07
• Status Verified: 2018-07
• Last Update Submitted: 2018-07-12
• Last Update Posted: 2018-07-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 93

Inclusion Criteria

• Part I (SD):
• Male, aged 18-55 years (both inclusive) at the time of signing informed consent
• Body mass index (BMI) between 25.0 and 34.9 kg/m^2 (both inclusive). Overweight should be due to excess of adipose tissue, as judged by the investigator
• Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator
• Part II (MD):
• Male or female, aged 18-55 years (both inclusive) at the time of signing informed consent
• Body mass index (BMI) between 27.0 and 39.9 kg/m^2 (both inclusive). Overweight should be due to excess of adipose tissue, as judged by the investigator
• Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator

Read More

Exclusion Criteria

• Any clinically significant weight change (at least 5% self-reported change during the previous 3 months), dieting attempts (e.g. participation in an organised weight reduction programme within the last 3 months), prior obesity surgery, or medications affecting body weight within 3 months prior to screening
• Male subjects who are not surgically sterilised (vasectomy) and are sexually active with female partner(s) who are not using a highly effective method of contraception (such as condom with spermicide) combined with a highly effective method of contraception for their non-pregnant female partner(s) (Pearl Index 1%, such as implants, injectables, oral contraceptives, intrauterine devices, diaphragm or cervical cap+spermicide), and/or intend to donate sperm in the period from screening until 3 months following administration of the investigational medical product
• Female subjects who are of child bearing potential (pre-menopausal and not surgically sterilised) and are sexually active with male partner(s) who are not surgically sterilised (vasectomy) and are not using highly effective contraceptive methods (Pearl Index 1%,such as implants, injectables, oral contraceptives, intrauterine devices, diaphragm or cervical cap+spermicide) combined with a highly effective method of contraception for their male partner(s) (e.g. condom with spermicide), and/or are pregnant, breast-feeding or intend to become pregnant) (applicable to Part II (MD) only)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Placebo	placebo	-
NNC0165-1562	NNC0165-1562	-

Primary Outcome Measures

Name	Time	Method
Number of treatment emergent adverse events (TEAEs), Part I (SD)	From time of dosing (Day1) until completion of the follow-up visit (Day 29)
Number of TEAEs, Part II (MD)	From time of dosing (Day 1) until completion of the follow-up visit (Day 85)

Secondary Outcome Measures

Name	Time	Method
The area under the NNC0165-1562 plasma concentration-time curve, Part II (MD)	From time 0 to 24 hours at steady state. From baseline (Day 1) until the follow-up visit (Day 85)
The area under the NNC0165-1562 plasma concentration-time curve, Part I (SD)	From time 0 to 24 hours after a single s.c. dose. From baseline (Day 1) until the follow-up visit (Day 29)
The maximum plasma concentration of NNC0165-1562 after a single s.c. dose, Part I (SD)	From baseline (Day 1) until the follow-up visit (Day 29)
The time to maximum plasma concentration of NNC0165-1562 at steady state, Part II (MD)	From baseline (Day 1) until the follow-up visit (Day 85)
The time to maximum plasma concentration of NNC0165-1562 after a single s.c.dose, Part I (SD)	From baseline (Day 1) until the follow-up visit (Day 29)
The maximum plasma concentration of NNC0165-1562 at steady state, Part II (MD)	From baseline (Day 1) until the follow-up visit (Day 85)

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇺🇸 Tempe, Arizona, United States